Arcturus Therapeutics (ARCT) News Today $12.77 -0.50 (-3.77%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$12.64 -0.13 (-1.01%) As of 03/25/2025 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Bank of New York Mellon Corp Sells 22,024 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)Bank of New York Mellon Corp trimmed its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 22.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 78,180 shares of the biotechnology company's stock after selliMarch 24 at 3:06 AM | marketbeat.comIs Arcturus Therapeutics (ARCT) a Worst High-Risk High-Reward Growth Stock to Buy?March 20, 2025 | insidermonkey.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by Nikko Asset Management Americas Inc.Nikko Asset Management Americas Inc. reduced its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 10.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,065,050 shares of the biotechnoMarch 18, 2025 | marketbeat.comWilliam Blair Issues Negative Estimate for ARCT EarningsMarch 18, 2025 | americanbankingnews.com2 Growth Stocks to Buy Now With 367% to 410% UpsideMarch 17, 2025 | msn.comWilliam Blair Issues Pessimistic Outlook for ARCT EarningsArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) - Equities researchers at William Blair dropped their Q1 2025 earnings per share (EPS) estimates for Arcturus Therapeutics in a research report issued to clients and investors on Thursday, March 13th. William Blair analyst M. MinterMarch 17, 2025 | marketbeat.comJupiter Asset Management Ltd. Lowers Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)Jupiter Asset Management Ltd. lessened its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 9.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 319,446 shares of tMarch 14, 2025 | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by Bank Julius Baer & Co. Ltd ZurichBank Julius Baer & Co. Ltd Zurich lowered its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 91.8% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,084 shares of the biotechnology company's stock after selling 23,20March 12, 2025 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Price Target Lowered to $68.00 at Canaccord Genuity GroupCanaccord Genuity Group decreased their price target on shares of Arcturus Therapeutics from $74.00 to $68.00 and set a "buy" rating for the company in a report on Monday.March 10, 2025 | marketbeat.comArcturus Therapeutics price target lowered to $68 from $74 at CanaccordMarch 10, 2025 | markets.businessinsider.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) have earned a consensus rating of "Buy" from the eight research firms that are covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has assigned a stMarch 10, 2025 | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Are Cutting Their Estimates: Here's What You Need To KnowMarch 9, 2025 | finance.yahoo.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2024 Earnings Call TranscriptMarch 8, 2025 | msn.comArcturus Therapeutics (NASDAQ:ARCT) Price Target Lowered to $60.00 at HC WainwrightHC Wainwright decreased their price target on shares of Arcturus Therapeutics from $63.00 to $60.00 and set a "buy" rating on the stock in a research note on Friday.March 8, 2025 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Receives Overweight Rating from Cantor FitzgeraldCantor Fitzgerald reissued an "overweight" rating on shares of Arcturus Therapeutics in a research report on Friday.March 8, 2025 | marketbeat.comWells Fargo & Company Has Lowered Expectations for Arcturus Therapeutics (NASDAQ:ARCT) Stock PriceWells Fargo & Company decreased their price target on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an "overweight" rating for the company in a research note on Friday.March 8, 2025 | marketbeat.comQ4 2024 Arcturus Therapeutics Holdings Inc Earnings CallMarch 7, 2025 | finance.yahoo.comArcturus Therapeutics (ARCT) Gets a Buy from Wells FargoMarch 7, 2025 | markets.businessinsider.comBeyond The Numbers: 8 Analysts Discuss Arcturus Therapeutics StockMarch 7, 2025 | benzinga.comArcturus Therapeutics price target lowered to $60 from $63 at H.C. WainwrightMarch 7, 2025 | markets.businessinsider.comArcturus Therapeutics (NASDAQ:ARCT) Issues Earnings Results, Misses Expectations By $0.78 EPSArcturus Therapeutics (NASDAQ:ARCT - Get Free Report) issued its earnings results on Thursday. The biotechnology company reported ($1.11) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.78). Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%.March 7, 2025 | marketbeat.comArcturus Therapeutics Holdings Inc. (ARCT) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | seekingalpha.comArcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline ProgressMarch 6, 2025 | businesswire.comArcturus Therapeutics to Present at Leerink’s Global Healthcare Conference 2025March 5, 2025 | finance.yahoo.comArcturus Therapeutics (ARCT) Projected to Post Earnings on ThursdayArcturus Therapeutics (NASDAQ:ARCT) will be releasing earnings after the market closes on Thursday, March 6, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=669475)February 27, 2025 | marketbeat.comArcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025February 26, 2025 | businesswire.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock Holdings Lessened by ARK Investment Management LLCARK Investment Management LLC reduced its holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 8.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 1,933,851 shares of the biotechnology company's stock after sellinFebruary 26, 2025 | marketbeat.comBTIG Remains a Buy on Arcturus Therapeutics (ARCT)February 25, 2025 | markets.businessinsider.comArcturus Therapeutics (NASDAQ:ARCT) Share Price Passes Below 200-Day Moving Average - Here's WhyArcturus Therapeutics (NASDAQ:ARCT) Stock Crosses Below Two Hundred Day Moving Average - Should You Sell?February 25, 2025 | marketbeat.comArcturus Therapeutics price target raised to $48 from $41 at BTIGFebruary 18, 2025 | markets.businessinsider.comShort Interest in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Declines By 9.9%Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) was the target of a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 4,540,000 shares, a drop of 9.9% from the January 15th total of 5,040,000 shares. Approximately 18.5% of the company's stock are sold short. Based on an average daily trading volume, of 429,700 shares, the short-interest ratio is presently 10.6 days.February 17, 2025 | marketbeat.comEmpire Life Investments Inc. Raises Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)Empire Life Investments Inc. increased its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 85.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 279,463 sharesFebruary 16, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Arcturus Therapeutics (NASDAQ:ARCT)HC Wainwright reissued a "buy" rating and issued a $63.00 price objective on shares of Arcturus Therapeutics in a research note on Friday.February 15, 2025 | marketbeat.comCSL, Arcturus Therapeutics announce European Commission approval for KostaiveFebruary 14, 2025 | markets.businessinsider.comArcturus Therapeutics and CSL’s Kostaive COVID-19 vaccine approved in EuropeFebruary 14, 2025 | markets.businessinsider.comBreaking Down Arcturus Therapeutics: 5 Analysts Share Their ViewsFebruary 14, 2025 | benzinga.comEuropean Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 VaccineFebruary 14, 2025 | prnewswire.comEuropean Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 VaccineFebruary 14, 2025 | businesswire.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Rating of "Buy" by BrokeragesArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) has been assigned an average rating of "Buy" from the seven research firms that are currently covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating and one has issued a strong buy ratFebruary 13, 2025 | marketbeat.comSumitomo Mitsui Trust Group Inc. Decreases Stock Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)Sumitomo Mitsui Trust Group Inc. decreased its holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 9.3% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,065,050 shares of the biotechnology company's stock after sFebruary 12, 2025 | marketbeat.comArcturus Therapeutics appoints Moncef Slaoui as chair designateFebruary 4, 2025 | markets.businessinsider.comArcturus Therapeutics names Moncef Slaoui as Chair DesignateFebruary 4, 2025 | msn.comArcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair DesignateFebruary 4, 2025 | finance.yahoo.comShort Interest in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Rises By 8.6%Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) was the target of a large growth in short interest in January. As of January 15th, there was short interest totalling 4,820,000 shares, a growth of 8.6% from the December 31st total of 4,440,000 shares. Approximately 19.6% of the shares of the company are sold short. Based on an average daily volume of 400,900 shares, the days-to-cover ratio is currently 12.0 days.February 2, 2025 | marketbeat.comEd Arce’s Buy Rating on Arcturus Therapeutics Driven by Strategic Advancements and Strong Market PositioningJanuary 31, 2025 | markets.businessinsider.comMeiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19January 31, 2025 | businesswire.comH.C. Wainwright Keeps Their Hold Rating on Durect (DRRX)January 29, 2025 | markets.businessinsider.comBTIG Initiates Coverage of Arcturus Therapeutics Holdings (ARCT) with Buy RecommendationJanuary 29, 2025 | msn.comArcturus Therapeutics' SWOT analysis: mRNA innovator's stock faces pivotal yearJanuary 28, 2025 | msn.comArcturus: Downgrading As mRNA Promise Meets Market RealityJanuary 28, 2025 | seekingalpha.com Remove Ads Get Arcturus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Email Address ARCT Media Mentions By Week ARCT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARCT News Sentiment▼0.270.77▲Average Medical News Sentiment ARCT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARCT Articles This Week▼44▲ARCT Articles Average Week Remove Ads Get Arcturus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ANI Pharmaceuticals News Dyne Therapeutics News Indivior News Amphastar Pharmaceuticals News 89bio News Adaptive Biotechnologies News Evotec News ARS Pharmaceuticals News Ardelyx News Ocular Therapeutix News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARCT) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ARCT Stock Free ARCT Stock Alerts